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ABSTRACT 
Objective: The aim of the present investigation is to formulate and evaluate amphotericin B-miltefosine combination nanovesicles for application in 
the treatment of visceral leishmaniasis.  
Methods: Amphotericin B-miltefosine combination (AmB-MTF) nanovesicles were prepared by ethanol injection method. Formulations of 
nanovesicles were evaluated at varying conditions of lipids composition, drug-lipid proportion, ethanol-water composition and stirring rate, on 
drug entrapment efficiency and particle size.  
Results: The study showed that entrapment efficiency was significantly affected (p<0.01) by the effects of lipids composition, drug-lipid proportion, 
ethanol-water composition, and stirring rate. Particle size of nanovesicles was significantly affected (p<0.05) by drug-lipid proportion and stirring 
rate. An optimized formulation of amphotericin B-miltefosine nanovesicles was prepared at optimal factors composition of: phosphatidylcholine-
cholesterol-stearic acid 20:4:1, drug-lipid 1:8, AmB-MTF 1:1; ethanol-water 1:4 ratios, and stirring rate 1000 rpm. The AmB-MTF 1:1 nanovesicles 
formulation showed particle size of 145.6 nm, poly dispersity index 0.19, zeta potential-27.3 mV and drug entrapment efficiency 87%. 
Conclusion: Evaluation of AmB-MTF 1:1 nanovesicles showed development of a successful formulation with very good compatibility, extended drug 
release, convenient vesicle size and high drug entrapment efficiency. To conclude, AmB-MTF 1:1 nanovesicles formulation could be a safe and reliable 
therapeutic option over the conventional combination therapy provided further antileishmanial investigations are investigated in vitro and in vivo.  
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INTRODUCTION 
Visceral leishmaniasis is the most severe form of leishmaniasis by 
which patients nearly always die if untreated. It causes half a million 
new cases and 50,000 deaths each year. Visceral leishmaniasis 
remains to be a challenge for poor people in developing countries. 
The current treatment for visceral leishmaniasis is with drugs 
developed 50 y ago. Pharmaceutical companies are not attracted for 
developing new therapeutic options for neglected infectious 
diseases due to low incentives in the area [1, 2].  
Hence, the best strategy that remains as effective solution in crisis 
associated with the neglected diseases is using combination of the 
exciting drugs and developing novel drug delivery systems to 
improve the efficacy, specificity, tolerability, and emergence of 
resistance of existing antiparasitic agents [3]. Nanocarriers drug 
delivery to the liver and spleen, the main infection site of visceral 
leishmaniasis, have been developed [4]. Ambisome is the most 
effective and safe amphotericin B lipid liposomal formulation 
currently available on market. However, ambisome monotherapy 
unresponsiveness and drug resistance cases have also been reported 
in some places such as Bahir, India [5]. 
In combating the risk of resistance and to increase the efficacy of the 
existing drugs, WHO recommended use of combination of drugs. 
WHO recommended the use of liposomal AmB (5 mg/kg by infusion, 
single dose) and miltefosine (daily for 7 d orally) for the treatment 
of visceral leishmaniasis caused by L. donovani in Bangladesh, 
Bhutan, India and Nepal. This decreases the treatment duration by 
monotherapy from 28 d of miltefosine and 6-10 d of liposomal AmB 
to only 7 d combination therapy at reduced total exposure of each 
drug to patients [1, 6]. However, the two drugs are given in different 
routes and as separate dosage forms, and miltefosine is given in its 
conventional delivery that has significant gastrointestinal 
disturbances and hemolytic effects. Thus, the objective of the 
present investigation is to formulate and evaluate AmB-MTF 
combination lipid nanovesicles in a single dosage form and for 
targeted drug delivery to infection sites in the treatment of visceral 
leishmaniasis. 
MATERIALS AND METHODS 
Materials 
Amphotericin B (Sigma St Louis, USA), miltefosine (Cayman 
chemicals, USA), phosphatidylcholine (Spectrum chemicals, USA), 
cholesterol (MB Biomedicals, USA), oleic acid (Fisher; USA), lecithin 
(Fisher; USA) and stearic acid (Fisher; USA) were purchased. 
Distilled water, tween 80 (Fisher chemicals; USA), methanol (Fisher 
chemicals; USA), ethyl alcohol (Dacon Laboratories, USA), dimethyl 
sulfoxide (Fisher chemicals, USA), phosphate buffered saline tablets 
(Fisher chemicals, USA), and all other reagents were all used as 
received. All chemicals used were analytical grade. 
Methods  
Preparation of nanovesicles 
Drug loaded nanovesicles were prepared using ethanol injection 
technique based on Tanga et al. [7]. Accurately weighed AmB was 
dissolved in dimethyl sulfoxide (DMSO) to form 25 mg/ml solution. 
Specified amounts of lipids and 5 mg of miltefosine were accurately 
measured and dissolved in ethanol and heated to 75 °C as per the 
compositions given in table 1. A required amount of AmB solution 
was preheated to 75 °C and added to the lipid solution. The ethanolic 
solution was kept in sonicator bath for about 10 min to dissolve the 
entire content in ethanol with the end point as a clear yellowish 
solution. This solution was heated to 75 °C in the hot plate water 
bath (Heidolph magnetic stirrers 0416, Germany), injected into 
phosphate buffer saline (PBS) (pH 7.4) aqueous medium preheated 
at 75 °C in a round bottom flask, stirred continuously at a required 
rate for 5 min and probe sonicated (Microson TM, XL2000, USA) for 
1 minute at a frequency of 20 kHz. The hot water bath was removed 
and the magnetic stirring was further continued at the same speed 
for about 15 min to bring the system to room temperature. Ethanol 
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was removed from the preparation by using rotavapor (Heidolph 
Bushi Rotavapor, R-114, Germany). Finally, the vesicular dispersion 
was stored in airtight amber glass container at 2-8 °C.  
Drug entrapment efficiency 
Drug entrapment efficiency (DEE) was estimated according to 
Lankallapalli et al., and Bose et al., [8,9]. Nanovesicles suspension 
containing an equivalent of 1 mg AmB was diluted 1 to 5 with DMSO-
distilled water (1:25 v/v) and centrifuged (Eppendruf AG 5404, 
Germany) at 20,000g for 30 min at 4 °C. The supernatant was carefully 
separated and kept in a separate glass tube. For entrapped drug, the 
precipitate was dissolved in 5 ml DMSO-methanol (1:5 v/v). 1 ml of 
this solution was diluted appropriately to make a solution of 20 ml in 
DMSO-methanol-water (1:4:5 v/v) and AmB was determined directly 
from this solution at 408 nm using UV-Vis spectroscopy (Hitachi-2910, 
Japan). For the unentrapped drug, 1 ml of the clear supernatant 
solution collected previously was diluted appropriately to form 5 ml 
solution in DMSO-methanol-water (1:4:5) and AmB was determined 
directly from this solution at 408 nm. The total drug content was 
obtained as sum of drug content in the supernatant and in the 
precipitate. The AmB entrapment efficiency was calculated by using 
the following formula. In the case of miltefosine, entrapment efficiency 
is considered to be 100%, because it is the structural part of the 





Particle size and zeta potential determination  
The average particle size, polydispersity index (PDI) and zeta 
potential measurements were evaluated by dynamic light scattering 
technique. All analyses were carried out using Zeta sizer (Zita sizer, 
USA) for nanoparticles. The measurements of particle size, 
polydispersity index and zeta potential for each sample were carried 
out in triplicates and reported as mean values [11]. 
In vitro drug release studies 
In vitro release of AmB from nanovesicles was evaluated by the 
dialysis bag diffusion technique [9, 12]. Sample of nanovesicles 
suspension equivalent to 2 mg AmB was diluted to 5 ml in PBS (pH 
7.4). The resulting 5 ml solution was transferred to dialysis tubing 
(MW cutt-off 14,000 Da, Ward’s science, USA) which has been 
priorly soaked for 15 min in distilled water. The dialysis tubing with 
the 5 ml sample in was sealed at both ends, and immersed into a 
receptor compartment containing 95 ml dissolution medium of PBS 
(pH 7.4) and 1% tween 80. The receptor compartment was stirred at 
100 rpm and maintained at 37±0.5 °C. The receptor compartment 
was covered to prevent the evaporation of release medium. 2 ml of 
samples were withdrawn at time intervals (0, 2, 4, 6, 12, 24, 48 and 
72 h), and the same volume was replaced by fresh medium at same 
temperature. The sample solutions in DMSO-methanol-water (1:4:5) 
were prepared using appropriate dilution and were analyzed by UV-
Vis spectroscopy at 408 nm. All the experiments were performed in 
triplicate, and the average values were taken.  
Fourier transform infrared spectroscopy 
The Fourier transform infrared (FTIR) spectra of AmB and 
miltefosine plain drugs, and freeze-dried AmB-MTF nanovesicle 
formulations were analyzed using a FTIR spectrophotometer 
(Thermo Nicholet 6700, Portugal) [11, 12]. Samples were diluted 
with KBr powder in a pellet die, and the mixture was pressed at high 
pressure gauge to form a thin transparent disc. The FTIR 
measurements were performed at wave numbers ranging from 4000 
to 450 cm−1 at constant rate of 10 °C/minute under an argon purge.  
RESULTS AND DISCUSSION 
AmB-MTF nanovesicles were prepared by ethanol injection method. 
Nanovesicles were evaluated at different conditions of lipids 
composition, drug-lipid proportion, ethanol-water composition and 
stirring rate on drug entrapment efficiency and particle size. In the 
preparation of nanovesicles, ethanol soluble components; 
phosphatidylcholine (PC), cholesterol, stearic acid and miltefosine 
were first dissolved in ethanol at 75 °C to assure a homogeneous 
mixture of lipids for spontaneous formation of small unilamellar 
vesicles (SUVs) upon injection [12]. AmB was dissolved in DMSO (25 
mg/ml) to enhance its entrapment in nanovesicles. This is in accord 
with previous findings that the amount of poorly water soluble 
drugs encapsulated into vesicles is usually quite high with solvent 
aid [14]. Due to limited drug solubility in the external aqueous 
phase, the solubilized AmB in organic solvents tended to have a 
higher affinity to the phospholipid membrane components of the 
nanovesicles, thereby resulting in enhanced entrapment efficiency 
[14]. The concentration of lipids in ethanol solution was fixed at 
around 25 mg/ml to insure formation of SUVs in the vesicle 
formation. Studies showed that decreasing phospholipid 
concentrations in ethanol from 50 mg/ml to about 10 mg/ml 
produced SUVs of a significant lower particle size, although 
entrapment efficiency may be decreased as the lipid concentration 
decreased [15]. The effects of ingredients and process variables on 
nanovesicles formulations is presented in table 1.  
  
Table 1: Effects of different factors in preparation of AmB-MTF nanovesicles 
Factors  Particle size (nm) DEE (%)  
Stirring rate (rpm)  8 mg cholesterol, 30 mg PC, 1:10 AmB: lipid and 1:4 Ethanol: PBS. 
 500 196.3±6.9 81.45±2.26 
 1000 193.6±6.3 79.05±5.41 
 1200 167.6±14.6 67.97±2.96 
Lipid (mg) 1000 rpm,1:10 AmB: lipid, and 1:4 Ethanol: PBS, total lipid (40 mg) 
 Stearic acid, Oleic acid, Tween 80 (10:1:1) 171.5±10.7 37.41±4.8 
 Stearic acid,Lecithin, Cholesterol (0.5:7:2) 184.0±11.7 45.43±5.77 
 PC, Cholesterol (7:2) 192.5±9.0 77.63±2.73 
 Stearic acid, PC, Cholesterol (0.5:7:2) 193.3±6.9 93.07±3.19 
Drug: lipid (mg)  1000 rpm, 8 mg cholesterol, 30 mg PC, and 1:4 Ethanol: PBS. 
 1:5 202.6±1.7 61.26±4.39 
 1:10 192.5±6.3 79.43±5.49 
 1:20 169.7±17.4 88.54±3.31 
Ethanol-PBS(pH 7.4)  1000 rpm, 8 mg cholesterol, 30 mg PC, 1:10 AmB: lipid 
 2:1 --- --- 
 1:1 184.6±3.3 38.34±4.09 
 1:4 193.6±6.3 79.43±5.49 
Values represent mean±SD (n=3), weight of miltefosine in all formulations was 5 mg, total ethanol-water volume was 10 ml. 
 
Effect of stirring rate  
The effect of stirring rate on vesicle size and entrapment efficiency was 
assessed and the results are presented in table 1. In order to 
investigate the effect of stirring rate, formulations were prepared at 
500, 1000 and 1200 rpm while all other factors put at specified values 
in the table. The results showed particle size decreased from 193.6 to 
167.6 nm when the stirring rate was increased from 1000 to 1200 
rpm. The particle size also decreased from 196.3 to 193.6 nm by 
increasing stirring rate from 500 to 1000 rpm. Overall, the results 
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showed increasing stirring rate from 500 to 1200 rpm significantly 
decreased the size of nanovesicles from 196.3 to 167.6 nm (p<0.05). 
This may be due to the increased shearing action that has decreased 
aggregation of small vesicles leading to formation of smaller particle 
size vesicles [16]. The change in nanovesicles size due to stirring rate 
can also be explained by the intensification of micro mixing between 
the two phases, organic and aqueous during preparation that produces 
small droplets and hence small size vesicles [17]. 
Increasing stirring rate from 500 to 1200 rpm showed a decrease of 
entrapment efficiency from 81.45 to 67.97% (p<0.05). This decrease 
entrapment efficiency upon increasing the stirring rate may be due 
to the increased surface area of the nanovesicles that caused the 
drug molecules exposed to the surface leading more drug escape to 
the medium [18]. 
Effect of lipids  
Different lipids were evaluated for entrapment efficiency and particle 
size properties in the preparation of drug loaded nanovesicles (table 
1). Inclusion of PC and cholesterol showed an increased in entrapment 
efficiency up to 93.07%. Nanoparticles prepared from lecithin, stearic 
acid and cholesterol exhibited lower entrapment (45.43%) as 
compared to nanovesicles containing cholesterol, stearic acid and PC 
(93.07%). Nanoparticles prepared from lipids of stearic acid and oleic 
acid in the presence of tween 80 exhibited the lowest entrapment 
efficiency of 37.41%. It was evident from this that the inclusion of 
different types of lipids produced a significant effect on the 
entrapment efficiency (p<0.001). Entrapment of AmB increased from 
77.63 to 93.07% upon adding stearic acid (p<0.05). A similar study 
showed liposomes prepared with stearic acid had better entrapment 
efficiency, and stearic acid acted like cholesterol in stabilizing 
liposomal structure [19]. The increase in entrapment of AmB could 
also be due to the amine group of the drug interacted with the 
carboxylic headgroup of stearic acid through establishment of 
electrostatic interactions [20]. However, the average particle sizes of 
vesicles with and without stearic acid was 192.5 and 193.3 nm, 
respectively, showing that stearic acid didn’t cause a significant change 
in particle size of the vesicles. The effect of use of different lipids didn’t 
generally exhibit statistically significant change on particles size 
distribution of nanovesicles produced (p = 0.081).  
Effect of drug-lipid proportion 
The effect of drug-lipid proportion in nanovesicles preparation was 
assessed and presented in table 1. The results indicated increasing the 
proportion of AmB significantly affected the particle size and 
entrapment efficiency. The particle size is decreased from 202.6 to 
169.7 nm (p<0.05) with a decrease in the drug’s proportional from 1:5 
to 1:20. The decrease in particle size upon decreased initial loading of 
AmB could be due to the decrease in the viscosity of the organic phase 
with resultant higher diffusion of the lipid solution as small droplets 
into aqueous medium leading in lower particle size of nanovesicles. A 
similar study showed increasing initial loading of AmB increased the 
particle size with widened size distribution [21]. Decreasing the 
proportion of drug from 1:5 to 1:20 resulted in a significant increase in 
DEE from 61.26 to 88.54% (p<0.001). This shows decreasing the drug-
to-lipid ratio significantly enhanced the retention of the drug in the 
lipid. The increase in percent entrapment might be due to the presence 
of more internal phase in the lipid bilayer for dissolving the drug when 
lipid content is high [22]. The study also indicated the entrapment of 
AmB and stability of vesicles was found to be higher when the 
preparation temperature was about 75 °C as compared to lower 
temperatures such as 60 °C.  
Effect of ethanol-water composition 
The effect of different proportion of ethanol and water (PBS 
solution) in the process of vesicular preparations was investigated 
and the result is presented in table 1. At 2:1 ratio (66 % ethanol v/v 
in PBS), unstable preparation with sedimentation of drug at the 
bottom of the container was observed within hours, and those 
preparations were not further characterized. 1:1 (50%) and 1:4 
(20% ethanol v/v) ratios showed changes in entrapment efficiency 
of the drug in nanovesicles. An increase in ethanol percentage from 
20 to 50% caused the entrapment significantly decreased from 
79.43 to 38.4% (p<0.01). However, the effect of an increase of 
ethanol percentage from 20 to 50% on nanovesicles diameter wasn’t 
statistically significant (p = 0.09). 
In general, factors evaluation study was conducted to evaluate the 
effects of factors; lipids composition, drug lipid proportion, ethanol-
water composition and stirring rate on particle size and entrapment 
efficiency. The study demonstrated that, although particle size of 
vesicles were significantly affected by some of the factors, the vesicle 
sizes were still within the recommended rang of nanoparticles size 
from 100-250 nm for systemic drug delivery under all used ranges 
of the factors. However, drug entrapment efficiency was affected 
highly that ranges from 37.42 to 93.07% at varying compositions of 
the factors. All the factors also showed significant effects on drug 
entrapment efficiency (p<0.05), and the entrapment efficiency in 
some of the nanovesicles was very low. Thus, an optimal 
composition of factors was selected based on that to produce 
adequate entrapment efficiency. Hence, PC-cholesterol-stearic acid 
20:4:1, drug-lipid 1:8, ethanol-aqueous medium 1:4 and stirring rate 
1000 rpm were selected as optimal factors composition for optimal 
AmB-MTF nanovesicles formulation development in the optimized 
formulation study.  
AmB-MTF 1:1 nanovesicles formulation 
An optimal formulation of AmB-MTF nanovesicles was prepared at the 
chosen values: PC-cholesterol-stearic acid 20:4:1, drug-lipid 1:8, AmB-
MTF 1:1, ethanol-water 1:4, and stirring rate 1000 rpm. This optimal 
factors composition was chosen based on the factors evaluation study. 
The AmB and miltefosine proportion of AmB: MTF 1:1 (w/w) was 
choosen based on their therapeutic doses to patients, and preliminary 
AmB and miltefosine interaction study on promastigotes (data not 
shown here).  
AmB-MTF 1:1 nanovesicles showed vesicle size 145.6 nm, poly 
dispersity index (PDI) 0.19, zeta potential-27.3 mV and DEE 87% 
(table 2). PDI is used to describe the degree of non-uniformity of a 
size distribution of particles. According to international organization 
for standards (ISO), PDI values closer to 0 are seen with highly 
monodisperse standards, whereas PDI values 0.7-1.0 indicate that 
the sample has a very broad particle size distribution. In drug 
delivery applications using lipid-based carriers, a PDI of 0.3 and 
below is considered to be acceptable [23]. This may indicate the size 
distribution of AmB-MTF 1:1 nanovesicles (PDI = 0.19) is within the 
acceptable range. The relative smaller particle size and PDI values in 
AmB-MTF 1:1 nanovesicles can be due to the surfactant nature of 
miltefosine that could produce smaller and uniform sized droplets 
and hence smaller nanovesicles during preparation [24]. Zeta 
potential results of AmB-MTF nanovesicles was-27.3 mV, and AmB 
entrapment was 87.0%. Particle size and zeta potential distributions 
of AmB-MTF 1:1 nanovesicles are presented in fig. 1. 
In vitro drug release study  
The results of in vitro drug release study of the AmB-MTF 1:1 
nanovesicles formulation showed drug release of 99.51% in 72 h. It 
is also evident from the result that about 50% of AmB was released 
in the first 6 h, and about 93% of AmB was released in the first 24 h 
while the remaining undergo a more extended release up to a period 
of 72 h (fig. 2). The higher drug release rate of the poorly-water 
soluble AmB in the first 12 h may be due to the surfactant effect of 
miltefosine [25]. In vitro drug release study is performed in order to 
assess the potential of nanovesicles to control the release of drugs 
incorporated for prolonging the action [26].
  
Table 2: Particle size, PDI, Zeta potential and DEE evaluations of AmB-MTF nanovesicle 
Formulation Particle size (nm)  PDI Zeta potential (mV) DEE (%) 
AmB-MTF 1:1 nanovesicles 145.6±8.4 0.19±0.04 -27.3±2.8 87.0±4.2 
Values represent mean±SD (n =3) 
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Fig. 1: Particle size (nm) and zeta potential distributions (mV) of the AmB-MTF 1:1 nanovesicles 
 
 
Fig. 2: In vitro drug release profile of AmB-MTF 1:1 nanovesicles in PBS (pH 7.4) 
 
Drug-excipients interaction study 
Drug-excipients interaction was studied using Fourier transform 
infrared (FTIR) spectroscopy, and the results are presented in fig. 3. 
AmB demonstrates characteristic peaks in FTIR at 2920 cm−1 (due to 
its CH2 and CH3 stretching) and 3400 cm−1 (due to OH stretching) [27]. 
In this study, both plain AmB and AmB-MTF 1:1 nanovesicles showed 
these characteristic peaks of AmB at about the same wavelengths. 
Similarly, miltefosine exhibits its characteristic FTIR peaks at 2900 
cm−1 (CH2 stretching) and 1500 cm−1 (CH2 bending) [28]. The results of 
this study also illustrated plain AmB and miltefosine, and AmB-MTF 
1:1 nanovesicles showed these characteristic peaks at about the same 
wavelength. According to this study, there was no apparent interaction 
between the drugs and formulation excipients [29, 30].
 
 
Fig. 3: FTIR spectra of AmB, miltefosine and AmB-MTF nanovesicles 
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CONCLUSION 
AmB-MTF nanovesicles were prepared by the ethanol injection 
method. The study showed that entrapment efficiency was 
significantly affected (p<0.01) by the effects of lipids, drug-lipid 
proportion, ethanol-water composition and stirring rate. Particle 
size of the nanovesicles were significantly affected (p<0.05) by drug-
lipid proportion and stirring rate. The study also demonstrated that 
although both entrapment efficiency and particle size showed 
significant changes, drug entrapment efficiency was the most 
important response variable. Hence, an optimal composition of 
factors: PC-cholesterol-stearic acid 20:4:1, drug-lipid 1:8, ethanol-
aqueous medium 1:4 and stirring rate 1000 rpm was chosen based 
on that to produce adequate entrapment efficiency for optimal AmB-
MTF nanovesicles preparation. Hence, optimized AmB-MTF1:1 
nanovesicles was prepared at the chosen optimal factors composition, 
and its evaluation showed development of a successful formulation 
with very good compatibility, extended drug release, convenient 
particle size and high drug entrapment efficiency. This study 
concludes AmB-MTF 1:1 nanovesicles could be a safe and reliable 
therapeutic option over conventional AmB-MTF combination therapy. 
However, for the AmB-MTF 1:1 nanovesicles formulation to be used as 
better option of the conventional combinations in the treatment of 
visceral leishmaniasis, further antileishmanial investigations need to 
be conducted in vitro and in vivo.  
FUNDING 
The authors of this study would like to acknowledge the University 
of Gondar, Andhra University and the Ohio state university for their 
financial and material support. 
AUTHORS CONTRIBUTIONS 
All the authors listed in this manuscript have contributed equally. 
CONFLICT OF INTERESTS 
The author declares that there is no conflict of interest related to 
this report  
REFERENCES 
1. Musa A, Khalil E, Hailu A. Sodium stibogluconate-paromomycin 
combination for visceral leishmaniasis in East Africa 
randomized controlled trial. PLoS Negl Trop Dis 2012;6:1674. 
2. WHO. Leishmaniasis. Available from: https://www.who.int/ 
news-room/fact-sheets/detail/leishmaniasis. [Last accessed on 
12 Mar 2019]. 
3. Date AA, Joshi MS, Patravale VB. Parasitic diseases: liposomes 
and polymeric nanoparticles versus lipid nanoparticles. Adv 
Drug Delivery Rev 2007;59:505–21.  
4. Wagner V, Minguez Menendez A, Pena J, Fernandez Prada C. 
Innovative solutions for the control of leishmaniases: 
nanoscale drug delivery. Curr Pharm Design 2019;25:1582-92. 
5. Purkait B, Kumr A, Nandi N, Sardar A, Das S, Kumar S, et al. 
Mechanism of amphotericin B resistance in clinical isolates of 
leishmanial donovani. Antimicrob Agents Chemother 
2012;56:1031-41.  
6. Shaw CD, Carter KC. Drug delivery: lessons to be learnt from 
Leishmania studies. Nanomedicine 2014;9:1531-44.  
7. Tanga J, Srinivasanb S, Yuana W, Minga R. Development of a 
flow-through USP 4 apparatus drug release assay for the 
evaluation of amphotericin B liposome. Eur J Pharm Biopharm 
2019;134:107–16. 
8. Lankalapalli S, Tenneti VS, Nimmali SK. Design and 
development of vancomycin liposomes. Indian J Pharm Edu Res 
2015;49:208-15. 
9. Bose P, Kumar P, Dwivedi M. Hemoglobin guided nanocarrier 
for specific delivery of amphotericin B to Leishmania infected 
macrophage. Acta Trop 2016;15:148-59. 
10. Momeni A, Rasoolian M, Momeni A, Navaei A. Development of 
liposomes loaded with antileishmanial drugs for the treatment 
of cutaneous leishmaniasis. J Liposome Res 2013;23:134–44. 
11. AL-Quadeib BT, Radwan MA, Siller L, Horrocks B, Wrightd MC. 
Stealth amphotericin B nanoparticles for oral drug delivery: In 
vitro optimization. Saudi Pharm J 2015;23:290–302. 
12. Wan S, Zhang L, Quan Y, Wei K. Resveratrol-loaded PLGA 
nanoparticles: enhanced stability, solubility and bioactivity of 
resveratrol for non-alcoholic fatty liver disease therapy. Royal 
Soc Open Sci 2018;5:18145.  
13. Batzri S, Korn D. Single bilayer liposomes prepared without 
sonication. BBA–Biomembranes 1973;298:1015–9.  
14. Ong S, Ming L, Lee K, Yuen K. Influence of the encapsulation 
efficiency and size of liposome on the oral bioavailability of 
griseofulvin-loaded liposomes. Pharmaceutics 2016;8:25. 
15. Yang K, Delaney JT, Schubert US, Fahr A. Fast high-throughput 
screening of temoporfin-loaded liposomal formulations 
prepared by ethanol injection method. J Liposome Res 
2012;22:31–41.  
16. El-Say KM, Ahmed OA, Mohamed AI, Safo MK, Omar AM. El-Say 
KM, et al. Zein alpha lipoic acid-loaded nanoparticles to 
enhance the oral bioavailability of dapoxetine: optimization 
and clinical pharmacokinetic evaluation. Int J Nanomed 
2019;14:7461-73.  
17. Shariare MH, Blagden N, De Matas M, Leusen F. The impact of 
formulation attributes and process parameters on black seed 
oil loaded liposomes and their performance in animal models 
of analgesia. Saudi Pharm J 2012;25:404-12. 
18. Venkata NJ, Prasanna PM, Sakarkar SN, Prabha KS, Ramaiah PS. 
Microencapsulation techniques, factors influencing 
encapsulation efficiency. J Microencapsulation 2010;27:187–97.  
19. Hsieh YF, Chen TL, Wang YT, Chang JH, Chang HM. Properties of 
liposomes prepared with various lipids. J Food Sci 
2002;67:2808-13. 
20. Cengiz A, Kahyaoglu T, Schröenb C, Berton Carabin C. Oxidative 
stability of emulsions fortified with iron: the role of liposomal 
phospholipids. J Sci Food Agric 2019;99:2957–65. 
21. Italia JL, Sharp A, Carter KC, Warn P, Kumar R. Peroral 
amphotericin b polymer nanoparticles lead to comparable or 
superior in vivo antifungal activity to that of intravenous 
Ambisome® or Fungizone™. Plosone 2011;6:1-11. 
22. Kaur R, Sharma N, Tikoo K, Sinha VR. Development of 
mirtazapine loaded solid lipid nanoparticles for topical 
delivery: optimization, characterization and cytotoxicity 
evaluation. Int J Pharm 2020;586:119439. 
23. Danaei M, Dehghankhold M, Hasanzadeh AF, Javanmard DR, 
Mozafari MR. Impact of particle size and polydispersity index 
on the clinical applications of lipidic nanocarrier systems. 
Pharmaceutics 2018;10:57. 
24. Alonso L, Jeferson E, Cardoso S. Interactions of miltefosine with 
erythrocyte membrane proteins compared to those of ionic 
surfactants. Colloidal Surfaces B 2019;180:23-30. 
25. Efentakis M, Al-Hmoud H, Buckton G, Rajan Z. The influence of 
surfactants on drug release from a hydrophobic matrix. Int J 
Pharm 1991;70:153-8. 
26. Alvarez Berrios M, Aponte Reyes L, Diaz Figueroa L, Vivero 
Escoto J, Johnston A, Sanchez Rodriguez D. Preparation and in 
vitro evaluation of alginate microparticles containing 
amphotericin b for the treatment of candida infections. Int J 
Biomater 2020. https://doi.org/10.1155/2020/2514387. 
27. D’Souza S. A review of in vitro drug release test methods for 
nano-sized dosage forms. Adv Pharm 2014:1-12. 
https://doi.org/10.1155/2014/304757. 
28. Dorlo T, Eggelte T, Vriesa P, Beijnen J. Characterization and 
identification of suspected counterfeit miltefosine capsules. 
Analyst 2012;137:1265–74. 
29. Kunasekaran V, Krishnamoorthy K. Compatibility studies of 
rasagiline mesylate with selected excipients for an effective 
solid lipid nanoparticles formulation. Int J Pharm Pharm Sci 
2015;7:73-80.  
30. Dawood NM, Abdal-Hammid SN, Hussien AA. Formulation and 
characterization of lafutidine nanosuspension for oral drug 
delivery system. Int J Appl Pharm 2018;10:10-30. 
 
